Protease inhibitors enhance levodopa effects in Parkinson's disease.
Caparros-Lefebvre
D
D
Lannuzel
A
A
Tiberghien
F
F
Strobel
M
M
D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000378:metabolism*; D004357:Drug Synergism; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006801:Humans; D019469:Indinavir / Q000494:pharmacology*; D007980:Levodopa / Q000009:adverse effects* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D017320:HIV Protease Inhibitors; D007980:Levodopa; D019469:Indinavir